Back to top
more

Medpace (MEDP)

(Real Time Quote from BATS)

$430.39 USD

430.39
129,998

-5.91 (-1.36%)

Updated Aug 6, 2025 12:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (73 out of 246)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Exact Sciences (EXAS) to Showcase Favorable Research Outcome

by Zacks Equity Research

Exact Sciences' (EXAS) latest study research result shows commitment to innovation and strategies that expand access to effective cancer screening and diagnostic tools for patients.

Zacks Equity Research

Here's Why Investors Should Retain ICON (ICLR) Stock Now

by Zacks Equity Research

Investors remain optimistic about ICON (ICLR) due to its impressive strategic pacts and stable solvency.

Zacks Equity Research

Stereotaxis (STXS) Gets CE Recertification for Approved Products

by Zacks Equity Research

Stereotaxis' (STXS) receives updated EU Quality Management System Certificate, which demonstrates compliance with MDR.

Zacks Equity Research

Here's Why You Should Buy Boston Scientific (BSX) Stock Now

by Zacks Equity Research

Investors continue to be optimistic about Boston Scientific (BSX) due to its geographical expansions and impressive acquisitions.

Zacks Equity Research

Charles River (CRL) Banks on RMS Growth Amid Competition

by Zacks Equity Research

Charles River's (CRL) RMS arm sees lesser impact on demand than other life science sectors despite macroeconomic challenges in China.

Zacks Equity Research

Here's Why You Should Retain Edward Lifesciences (EW) for Now

by Zacks Equity Research

Investors are optimistic about Edward Lifesciences (EW), led by the strong performance of its SAPIEN 3 Ultra RESILIA platform and strong solvency.

Zacks Equity Research

Zacks Market Edge Highlights: Wingstop, Super Micro Computer, Medpace, Him & Hers Health and Vita Coco

by Zacks Equity Research

Wingstop, Super Micro Computer, Medpace, Him & Hers Health and Vita Coco are part of the Zacks Market Edge blog.

Zacks Equity Research

Medtronic's (MDT) OmniaSecure Lead Favored in the LEADR Trial

by Zacks Equity Research

Medtronic's (MDT) OmniaSecure defibrillation lead demonstrates reliable performance in the LEADR Pivotal trial.

Zacks Equity Research

Reasons to Include Alcon (ALC) in Your Portfolio Right Now

by Zacks Equity Research

New product launches and strong solvency bode well for Alcon (ALC).

Tracey Ryniec headshot

5 Top Ranked Strong Buy Growth Stocks for 2024

by Tracey Ryniec

Get double digit earnings growth this year.

Zacks Equity Research

Centene (CNC), Cityblock Partner to Enhance Value-Based Care

by Zacks Equity Research

Centene (CNC) collaborates with Cityblock to provide comprehensive care services to Central Florida's Medicaid members.

Zacks Equity Research

Medtronic (MDT) Q4 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

Growth across Cranial & Spinal Technologies, Diabetes, Cardiac Pacing and Surgical businesses contributes to Medtronic's (MDT) Q4 revenues.

Zacks Equity Research

Here's Why You Should Retain Walgreens Boots (WBA) For Now

by Zacks Equity Research

Investors are optimistic about Walgreens Boots (WBA), led by strategic alliances and new product launches.

Zacks Equity Research

Boston Scientific (BSX) Rides on Emerging Markets, MedSurg

by Zacks Equity Research

Boston Scientific's (BSX) Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of GI and pulmonary treatment options.

Zacks Equity Research

Veracyte's (VCYT) New Findings to Advance Thyroid Cancer Care

by Zacks Equity Research

Veracyte's (VCYT) new studies leverage Afirma GRID's whole-transcriptome approach to uncover novel molecular signatures and alterations.

Zacks Equity Research

Globus Medical (GMED) Hits 52-Week High: What's Driving It?

by Zacks Equity Research

Globus Medical (GMED) outperforms the industry due to its stellar quarterly performance and impactful launches.

Zacks Equity Research

Intuitive Surgical (ISRG) Hits 52-Week High on Procedure Demand

by Zacks Equity Research

Intuitive Surgical's (ISRG) da Vinci procedure volume, coupled with strong Ion procedure growth, is fueling the rally in the company???s share price.

Zacks Equity Research

CVS Health (CVS) Expands Food and Beverage Line With New Launch

by Zacks Equity Research

CVS Health's (CVS) Well Market brand offers a blend of mouthwatering flavors and nutritious options, expertly crafted and taste-tested by food enthusiasts.

Zacks Equity Research

Bruker (BRKR) Gains Market Share on Innovation Amid Macro Woes

by Zacks Equity Research

Bruker's (BRKR) BSI Nano business is seeing robust revenue growth across its end markets, including academic, government, industrial and semiconductor metrology.

Zacks Equity Research

Here's Why You Should Buy Haemonetics (HAE) Stock Now

by Zacks Equity Research

Strong prospects of the Plasma franchise and favorable solvency bode well for Haemonetics (HAE).

Zacks Equity Research

Medtronic's (MDT) MiniMed 780G AID System Wins New Accolade

by Zacks Equity Research

Medtronic's (MDT) MiniMed 780G system gets recognized among Fast Company's 2024 World Changing Ideas.

Zacks Equity Research

Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?

by Zacks Equity Research

Sector ETF report for FXH

Zacks Equity Research

Evolus (EOLS) Releases Favorable Dermal Fillers Study Data

by Zacks Equity Research

The addition of Evolysse fillers to the company's portfolio complements Evolus' (EOLS) flagship neurotoxin Jeuveau.

Zacks Equity Research

McKesson (MCK) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about McKesson's (MCK) strength in its Biologics business.

Zacks Equity Research

Veracyte (VCYT) Up 6% Since Last Earnings: Will it Continue?

by Zacks Equity Research

Investors are optimistic about Veracyte (VCYT) led by strength in the testing business and upbeat guidance.